Grade 3 meningiomas exhibit aggressive growth patterns, and limited empirical studies and reported findings suggest a resemblance to cancerous cell growth patterns. Recognizing this can help patients and caregivers feel understood and supported as they face a challenging diagnosis. I am certain the Neuro-Oncologist who provided you with the information you shared obtained it from the limited reporting. As a Neuro-Behavioral Psychologist, I have the distinct honor of working alongside 2 of the leading scholar-practitioners (a Neurologist-Neuro-Oncologist and a Neurosurgeon-Neuro-Ophthalmologist) whose work is dedicated solely to meningioma brain tumors.
Known Facts:
*To date, there is no known cause or cure for meningioma brain tumors.
*Meningiomas do have a higher prevalence rate in women and an even higher rate of occurrence in women of color, particularly African American women, ages 50-70.
* The rise of current lawsuits regarding the increase in female hormones does not address estrogen (although HRT has been alluded to in retrospective studies [whereas this approach has extreme limitations, with data quality] ) as a contributing factor to the increase in meningioma brain tumors in women; however, scientific evidence identifies progestogen (found in Depo-Provera birth control) to be a known culprit.
* No matter the Grade, location, or treatment protocols used, this brain disease has debilitating outcomes for a vast majority of us who are survivors-thrivers. I speak from lived experience.

Congress allocates hundreds of millions of dollars annually, funds I have seen during my decade as a National Brain Tumor Society Ambassador, to support brain tumor research. Most of this funding targets childhood brain cancer and aggressive adult tumors, not meningioma brain tumors.

Because there is no direct link between pharmaceuticals used in treatment and meningioma development, funding for meningioma research remains limited. Women's health and advocacy are underfunded and less prioritized within the healthcare ecosystem, affecting research and services. Go Well...